Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials

Fig. 4

Radiographic response of patients with advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma treated with Zolbetuximab plus chemotherapy versus chemotherapy alone. (A) Objective response rate (ORR). (B) Disease control rate (DCR). (C) Complete response (CR). (D) Partial response (PR). (E) Stable disease (SD). (F) Progressive disease (PD)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us